Prostate Cancer Research Program (PCRP)

Prostate Cancer Research Program (PCRP) sits under the Army Medical Research and Development Command's CDMRP. It launched in 1997, received $75 million in FY26, and has distributed more than $2.445 billion cumulatively through FY25. Its mission is to improve outcomes for service members, veterans, and patients affected by prostate cancer, with a direct focus on reducing death and suffering. PCRP funds grants for universities, nonprofits, research organizations, and companies that can work on lethal disease, disparity reduction, progression biology, or quality of life. The program's four strategic goals are improving quality of life, developing new treatments for lethal prostate cancer, reducing disparities among high-risk groups, and understanding progression biology. Resources tied to the program include the Prostate Cancer Clinical Trials Consortium, the Prostate Cancer Project, and mentoring for new investigators. Prostate cancer accounted for 11.7 percent of cancer diagnoses among active duty personnel from 2005 to 2014, which explains the military connection in the portfolio. Proposals fit best when they speak to clinical impact, survivorship, or high-risk biology and can use the program's consortium-style infrastructure to sharpen the study design.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.